Identifying the autoantigens and T cell clonotypes driving immune attack in aplastic anemia to enable more precise diagnostics and targeted therapies.
Identifying GSPT1 as an essential, targetable vulnerability of skin-resident memory T cells to enable durable remission in chronic inflammatory skin diseases without systemic immunosuppression.
Building the largest cerebrospinal fluid immune profile dataset in pediatric autoimmune neurological diseases to enable faster, more accurate diagnosis of MS and related conditions.
Building a CHO cell surface display library of all human proteins to enable comprehensive, high-throughput autoantibody profiling across autoimmune diseases and vaccine responses.
Developing VCAM-1-targeted lipid nanoparticles delivering IL-10 mRNA to reduce neuroinflammation and improve outcomes after intracerebral hemorrhage.
Profiling deep immune changes before AAV relapse to identify predictive biomarkers and therapeutic targets for this difficult-to-manage autoimmune vasculitis.
Developing CART4-34, a novel CAR T cell therapy that selectively eliminates IGHV4-34+ pathogenic B cells in lupus while sparing healthy B cells and avoiding broad immunosuppression.
Building a spatial single-cell atlas of healthy and diseased human kidneys to redefine immune-mediated kidney disease and identify precision diagnostic and therapeutic targets.
Uncovering the mechanisms by which inflammasomes drive aberrant inflammation in humans to identify new therapeutic targets for autoinflammatory diseases and sepsis.
Advancing engineered CAR and CAAR T cell therapies across multiple autoimmune diseases through clinical trials, preclinical development, and industry partnerships.
